The Yale Cancer Center has announced the appointments of Thomas Prebet, MD, PhD, as Disease Aligned Research Team (DART) Leader for Myeloid Malignancies and Amer Zeidan, MBBS, as Director of the Hematology Early Therapeutics Program. In these new roles, Drs. Prebet and Zeidan will work closely with Stephanie Halene, MD, PhD, Interim Chief of Hematology at the Yale Cancer Center.
Dr. Prebet is Associate Professor of Medicine (Hematology) and is focused on developing clinical trials for myeloid malignancies and translational advances for patients with acute myeloid leukemia and myelodysplastic syndromes. In his new role as DART leader for myeloid malignancies, he will oversee the clinical trial team for myeloid malignancies and work to develop a complete portfolio of trials for patients.
Dr. Zeidan is Associate Professor of Medicine (Hematology) and is the Yale Principal Investigator for multiple National Cancer Institute–sponsored and clinical trials in myeloid malignancies. He is also chairing the steering committee for a large pharma-sponsored randomized trial of myelodysplastic syndromes. As Director of the Hematology Early Therapeutics Program, Dr. Zeidan will partner closely with Patricia LoRusso, DO, Associate Cancer Center Director for Experimental Therapeutics at the Yale Cancer Center, to develop a comprehensive phase I clinical trial portfolio for patients with hematologic malignancies.
